Tags

Type your tag names separated by a space and hit enter

Etidronate for hypercalcemia of malignancy and osteoporosis.
Am Fam Physician. 1991 Jun; 43(6):2155-9.AF

Abstract

The biphosphonates are becoming well established as effective agents for the treatment of metabolic bone diseases. Etidronate disodium is the only biphosphonate approved by the U.S. Food and Drug Administration. Accepted indications for etidronate therapy are symptomatic Paget's disease, heterotopic ossification and hypercalcemia of malignancy. An unapproved, but apparently successful use is treatment of postmenopausal osteoporosis. Both oral and intravenous preparations are available. Newer biphosphonates, which may be more efficacious and less toxic than etidronate, are being studied.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Hahnemann University School of Medicine, Philadelphia, Pennsylvania.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1904188

Citation

Horowitz, E, et al. "Etidronate for Hypercalcemia of Malignancy and Osteoporosis." American Family Physician, vol. 43, no. 6, 1991, pp. 2155-9.
Horowitz E, Miller JL, Rose LI. Etidronate for hypercalcemia of malignancy and osteoporosis. Am Fam Physician. 1991;43(6):2155-9.
Horowitz, E., Miller, J. L., & Rose, L. I. (1991). Etidronate for hypercalcemia of malignancy and osteoporosis. American Family Physician, 43(6), 2155-9.
Horowitz E, Miller JL, Rose LI. Etidronate for Hypercalcemia of Malignancy and Osteoporosis. Am Fam Physician. 1991;43(6):2155-9. PubMed PMID: 1904188.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Etidronate for hypercalcemia of malignancy and osteoporosis. AU - Horowitz,E, AU - Miller,J L, AU - Rose,L I, PY - 1991/6/1/pubmed PY - 1991/6/1/medline PY - 1991/6/1/entrez SP - 2155 EP - 9 JF - American family physician JO - Am Fam Physician VL - 43 IS - 6 N2 - The biphosphonates are becoming well established as effective agents for the treatment of metabolic bone diseases. Etidronate disodium is the only biphosphonate approved by the U.S. Food and Drug Administration. Accepted indications for etidronate therapy are symptomatic Paget's disease, heterotopic ossification and hypercalcemia of malignancy. An unapproved, but apparently successful use is treatment of postmenopausal osteoporosis. Both oral and intravenous preparations are available. Newer biphosphonates, which may be more efficacious and less toxic than etidronate, are being studied. SN - 0002-838X UR - https://www.unboundmedicine.com/medline/citation/1904188/Etidronate_for_hypercalcemia_of_malignancy_and_osteoporosis_ L2 - https://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -